Natural killer (NK) cells contribute to innate immune responses by killing virus-infected or malignantly transformed cells and by producing cytokines such as IFN-γ and TNF. NK cell activation is determined by a balance of signals from inhibitory and activating receptors. Because ligands of inhibitory receptors include MHC class I and class I-like molecules, the absence of self-MHC expression leads to NK activation (Cerwenka and Lanier, 2001). Approximately 20 receptors contribute to NK activation (Cerwenka and Lanier, 2001; Vivier et al., 2008). When ligands for activating receptors are sufficiently abundant, activating signals overcome inhibitory signals.

There are two currently accepted models for in vivo NK activation. One is that NK cells usually circulate in a naive state and are activated through interaction directly with ligands for pattern recognition receptors (PRRs) expressed by NK cells or interaction with cells that express PRR ligands (Hornung et al., 2002; Sivori et al., 2004). When pathogens enter the host, innate immune sensors, such as Toll-like receptors (TLRs), RIG-I-like receptors,

In myeloid dendritic cells (mDCs), TLR3 is expressed in the endosomal membrane and interacts with the adapter toll/interleukin 1 receptor homology domain-containing adaptor molecule 1 (TICAM-1; TRIF). TICAM-1 signals culminate in interferon (IFN) regulatory factor (IRF) 3 activation. Co-culture of mDC pretreated with the TLR3 ligand polyI:C and natural killer (NK) cells resulted in NK cell activation. This activation was triggered by cell-to-cell contact but not cytokines. Using expression profiling and gain/loss-of-function analyses of mDC genes, we tried to identify a TICAM-1–inducing membrane protein that participates in mDC-mediated NK activation. Of the nine candidates screened, one contained a tetraspanin-like sequence and satisfied the screening criteria. The protein, referred to as IRF-3–dependent NK-activating molecule (INAM), functioned in both the mDC and NK cell to facilitate NK activation. In the mDC, TICAM-1, IFN promoter stimulator 1, and IRF-3, but not IRF-7, were required for mDC-mediated NK activation. INAM was minimally expressed on NK cells, was up-regulated in response to polyI:C, and contributed to mDC–NK reciprocal activation via its cytoplasmic tail, which was crucial for the activation signal in NK cells. Adoptive transfer of INAM–expressing mDCs into mice implanted with NK-sensitive tumors caused NK–mediated tumor regression. We identified a new pathway for mDC–NK contact-mediated NK activation that is governed by a TLR signal–derived membrane molecule.

© 2010 Ebihara et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
NOD-like receptors, and lectin family proteins, which are PRRs, recognize a variety of microbial patterns (pathogen-associated molecular patterns [PAMPs]; Medzhitov and Janeway, 1997). Mouse NK cells express almost all TLRs (TLR1–3, 4, and 6–9), and some of these are directly activated by pathogens with the help of IL-12, IL-18, IFN-γ, and other cytokines (Newman and Riley, 2007). The other is that naive NK cells tend to be recruited to the draining LNs, where they are primed to be effectors with the help of mature myeloid DCs (mDC) and released into peripheral tissues (Fernandez et al., 1999). In this case, mDCs provide direct activating signals to NK cells through cell–cell contact (Gerosa et al., 2002; Akazawa et al., 2007a; Lucas et al., 2007). mDCs also produce proinflammatory cytokines and IFN-α after recognizing PAMPs (Newman and Riley, 2007). In this mDC-mediated NK activation, however, the molecules and mechanisms in mDC that are dedicated to NK activation in vivo remain to be understood.

In this study, we focused on the molecules that are induced in mDC during maturation by exposure to double-stranded (ds) RNA and the molecules involved in priming NK cells for target killing (Akazawa et al., 2007a). dsRNA of viral origin and the synthetic analogue poly(I:C) induce NK activation in concert with mDC in vivo and in vitro (Seya and Matsumoto, 2009). Poly(I:C) is recognized by the cytoplasmic proteins RIG-I/MDA5 and the membrane protein TLR3, both of which are expressed in mDC (Matsumoto and Seya, 2008). Although RIG-I and MDA5 in the cytoplasm deliver a signal to the adaptor protein IFN promoter stimulator 1 (IPS-1; also known as MAVS, VISA, and Cardif) on the outer membrane of the mitochondria (Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005), TLR3 in the endosomal membrane recruits the adaptor protein toll/IL-1 receptor homology domain–containing adaptor molecule 1 (TICAM-1)/TRIF (Oshiumi et al., 2003a; Yamamoto et al., 2003a). Both adaptor proteins activate TBK1 and/or IKK ε, which phosphorylate IFN regulatory factor (IRF) 3 and IRF-7 to induce type I IFN (Sasai et al., 2006). We previously showed that the TLR3–TICAM-1 pathway in mDC participates in inducing anti-tumor NK cytotoxicity by poly(I:C) (Akazawa et al., 2007a). mDC matured with poly(I:C) can enhance NK cytotoxicity through mDC–NK cell–cell contact (Akazawa et al., 2007a). Therefore, we hypothesized that an unidentified protein is up-regulated on the cell surface of mDC through activation of the TLR3–TICAM-1 pathway, and this protein enables mDC to interact with and activate NK cells. This is the first study identifying an IRF-3–dependent NK-activating molecule, which we abbreviated INAM. INAM is a TICAM-1–inducible molecule on the cell surface of BM-derived DCs (BMDCs) that activates NK cells via cell–cell contact. Our data imply that mDCs harbor a pathway for driving NK activation that acts in conjunction with dsRNA and TLR3.

RESULTS

TICAM-1/IRF-3 signal in BMDCs augments NK activation

An in vitro system for evaluating NK activation through BMDC–NK contact was established for this study (Fig. 1 A). A mouse melanoma cell subline B16D8, which was established in our laboratory as a low H-2 expressor (Mukai et al., 1999), was used as an NK target. Poly(I:C), WT BMDC, and NK cells were all found to be essential for NK-mediated B16D8 cytolyis in the in vitro assay (Fig. 1 A). Poly(I:C)-mediated NK activation was at baseline levels in a transwell with a 0.4-μm pore, suggesting the importance of direct BMDC–NK contact for this cytolyis induction (Fig. 1 A). When WT BMDCs were replaced with TICAM-1−/− BMDCs in this system, poly(I:C)-mediated NK activation was partly abolished (Fig. 1 B; and Fig. S1, A and B). TICAM-1 of BMDC was involved in driving NK activation, and ultimately B16D8 cells were damaged by BMDC-derived NK cells (Fig. 1 B). Poly(I:C)-mediated NK activation occurred even when WT NK cells were replaced with TICAM-1−/− NK cells (Fig. 1 B), which means that NK activation barely depends on the TICAM-1 pathway in NK cells.

Poly(I:C)-activated splenic NK cells were i.p. injected into B6 mice to kill B16D8 cells ex vivo, which is consistent with previous studies (McCartney et al., 2009; Miyake et al., 2009), and this poly(I:C)-mediated NK activation was markedly reduced in IPS-1−/− mice established in our laboratory (Fig. S1 C), suggesting that NK cell activation is induced via not only the TICAM-1 pathway but also the IPS-1 pathway, which was largely comparable with previous studies (McCartney et al., 2009; Miyake et al., 2009). IPS-1 in BMDC was more involved in poly(I:C)-driven NK cytotoxicity than TICAM-1 but almost equally contributed to NK-dependent IFN-γ induction to TICAM-1 in our setting (Fig. S1 B). In addition, the serum level of IL-12p40 in poly(I:C)-treated mice was largely dependent on TICAM-1 (Fig. S1 D; Kato et al., 2006; Akazawa et al., 2007a). In the supernatant of poly(I:C)-stimulated BMDC and the serum samples from poly(I:C)-treated mice, IL-12p70 was not detected by ELISA (unpublished data). These results suggest that poly(I:C) activates NK cells largely secondary to mDC maturation, which is sustained by the IPS-1 or TICAM-1 pathway of mDC. Even though NK cells express TLR3, they are only minimally activated by poly(I:C) alone. Signaling by TICAM-1 in BMDC can augment NK cytotoxicity and IFN-γ production via BMDC/NK contact.

The TICAM-1 pathway activates the transcription factor IRF-3. More precisely, exogenous addition of poly(I:C) can activate endosomal TLR3 and cytoplasmic RIG-I/MDA5. RIG-I/MDA5 assembles the adaptor IPS-1, which in turn recruits the NAP1–IKK-ε–TBK1 kinase (IKK) ε, which phosphorylate IRF-3 and IRF-7 to induce type I IFN (Sasai et al., 2006). For this reason, we examined the role of IRF-3 and IRF-7 in BMDC for activation of NK cells by poly(I:C). Activation of IRF-3, but not IRF-7, was required for BMDC to induce NK cytotoxicity (Fig. 1 C). IL-2 (Zanoni et al., 2005), IFN-α (Gerosa et al., 2002), and trans-presenting IL-15 (Lucas et al., 2007) induced by BMDC are reported to be key cytokines for BMDC–mediated NK activation in response to poly(I:C). However, even with normal levels of IFN-α production and IL-15 expression (Fig. 1, D and E), TICAM-1−/− BMDCs failed to induce full NK cytotoxicity (Fig. 1 B). In contrast, IRF-7−/− BMDCs, which have impaired IFN-α and IL-15...
from other tetraspanins like CD9, CD63, CD81, CD82, and CD151 in the predicted structure. Mouse INAM is a 40–55-kD protein with one N-glycosylation site and possesses four transmembrane motifs (Fig. 2, A and B). Western blotting analysis of INAM-transfected cells under nonreducing conditions showed no evidence of multimers (Fig. 2 B). The N-terminal and C-terminal regions of INAM are in the cytoplasm because anti-Flag antibody did not detect C-terminal Flag-tagged INAM until cells were permeabilized (unpublished data).

Alignment of the predicted amino acid sequence of mouse INAM with that of the human orthologue revealed that the two INAMs shared a 71.7% amino acid identity. INAM is also called FAM26F (Table S1) and is in the FAM26 gene family (Bertram et al., 2008; Dreses-Werringloer et al., 2008). Sequence database searches identified six mouse INAM paralogs. Although FAM26A/CALHM3, FAM26B/CALHM2, and FAM26C/CALHM1 are located on chromosome 19, FAM26D, FAM26E, and FAM26F/INAM are on chromosome 10. Only INAM was inducible with TLR agonists (unpublished data). All FAM26 family proteins have three or four transmembrane motifs predicted by the TMHMM Server (version 2.0). Human CALHM1 has a conserved region (Q/R/N site) expression, fully activated NK cells (Fig. 1, C–E). Hence, in BDMCs, the TICAM-1–IRF-3 pathway, rather than other cytokines, appears to induce cell surface molecules that mediate BMDC/NK contact and evoke NK cytotoxicity.

Identification of INAM

To identify the NK-activating cell surface molecule on BMDC, we performed microarray analysis on polyI:C-stimulated BMDC prepared from TICAM-1−/− BMDC from TICAM-1−/− and WT mice. The results yielded nine TICAM-1–inducible molecules with transmembrane motifs (Table S1). Six were induced in an IRF-3–dependent manner, whereas three were still induced in IRF-3−/− BMDC. The NK-activating ability of the products of these genes was investigated by introduction of lentivirus expression vector into IRF-3−/− BMDC. BMDCs with the transduced genes were co-cultured with WT NK cells and polyI:C, and the NK-activating ability was evaluated by determining IFN-γ in the 24-h co-culture. NK cells, but not the gene-transduced BMDCs, produced IFN-γ in the presence of polyI:C. Finally, we identified a tetraspanin-like molecule that satisfied our evaluation criteria (IFN-γ and cytotoxicity) on the mDC-NK activation and named this molecule INAM. INAM clearly differed from other tetraspanins like CD9, CD63, CD81, CD82, and CD151 in the predicted structure. Mouse INAM is a 40–55-kD protein with one N-glycosylation site and possesses four transmembrane motifs (Fig. 2, A and B). Western blotting analysis of INAM-transfected cells under nonreducing conditions showed no evidence of multimers (Fig. 2 B). The N-terminal and C-terminal regions of INAM are in the cytoplasm because anti-Flag antibody did not detect C-terminal Flag-tagged INAM until cells were permeabilized (unpublished data).

Alignment of the predicted amino acid sequence of mouse INAM with that of the human orthologue revealed that the two INAMs shared a 71.7% amino acid identity. INAM is also called FAM26F (Table S1) and is in the FAM26 gene family (Bertram et al., 2008; Dreses-Werringloer et al., 2008). Sequence database searches identified six mouse INAM paralogs. Although FAM26A/CALHM3, FAM26B/CALHM2, and FAM26C/CALHM1 are located on chromosome 19, FAM26D, FAM26E, and FAM26F/INAM are on chromosome 10. Only INAM was inducible with TLR agonists (unpublished data). All FAM26 family proteins have three or four transmembrane motifs predicted by the TMHMM Server (version 2.0). Human CALHM1 has a conserved region (Q/R/N site)
variety of TLRs (Iwasaki and Medzhitov, 2004), but other TLRs may be involved in parallel with those inducing NK activation. BMDCs express a

expression profile by polyI:C stimulation (Fig. S2 A). NKp46+ and DX5+ NK cells also increased by polyI:C stimulation (Fig. S2 A and not depicted). Notably, only CD45+ cells expressed INAM, which excludes the participation of contaminating stromal cells in the INAM expression. With ion channel properties at the C-terminal end of the second transmembrane motif that controls cytoplasmic Ca2+ levels (Dreses-Werringloer et al., 2008). However, the Q/R/N site was not found in INAM. CALHM1, 2, and 3 are highly expressed in brain. Quantitative RT-PCR revealed that INAM expression was high in spleen and LNs but low in thymus, liver, lung, and small intestine (Fig. 2 C), although expression of the other two FAM26 family members from chromosome 10 was highest in brain (not depicted). All splenocytes examined (CD3+, CD19+, DX5+, CD11b+, CD11c+, mDC (CD11c+PDCA1+), and plasmacytoid DC (CD11c+PDCA1+) expressed INAM to some levels (Fig. 2 D). The INAM expression was inducible by polyI:C in LN cells (Fig. 2 E); the induction levels were more prominent in myeloid cells than in lymphocytes in the LNs (Fig. S2 A). NKp46+ and DX5+ NK cells also expressed INAM with low levels and the levels were mildly increased by polyI:C stimulation (Fig. S2 A and not depicted). Notably, only CD45+ cells expressed INAM, which excludes the participation of contaminating stromal cells in the INAM up-regulation (Fig. S2 B).

**BMDC INAM activates NK cells**

WT and IRF-7−/− BMDCs induced high NK cytotoxicity in response to polyI:C, whereas TICAM-1−/−, IPS-1−/−, and IRF-3−/− BMDC showed less NK activation (Fig. 1, B and C; and Fig. S1). INAM expression profile by polyI:C stimulation was then examined using WT, IRF-3−/−, IRF-7−/−, and TICAM-1−/− BMDCs. Stimulation with polyI:C induced INAM at normal levels in IRF-7−/− BMDC but at decreased levels in IRF-3−/− and TICAM-1−/− BMDC (Fig. 3 A). The expression profiles of INAM in polyI:C-stimulated BMDC were in parallel with those inducing NK activation. BMDCs express a variety of TLRs (Iwasaki and Medzhitov, 2004), but other TLR ligands, Pam3CSK4, for TLR1/2, Malp2 for TLR2/6, and CpG for TLR9, barely induced INAM on BMDC. High induction of INAM was observed in BMDC stimulated with LPS as well as polyIC (Fig. 3 B), both of which can activate TICAM-1 to induce IRF-3 and IFN-α activation (Fitzgerald et al., 2003; Oshiumi et al., 2003a,b; Yamamoto et al., 2003a,b). Because INAM is an IFN-inducible gene (Fig. 3 B), INAM induction may be amplified by type I IFNs.

We next examined whether INAM was localized to the cell surface membrane in BMDC. Immunofluorescence analysis showed Flag-tagged INAM on the cell surface of BMDC. Plasma membrane expression of INAM was also confirmed by cell surface biotinylation (Fig. S3). Although the lentivirus inefficiently infected BMDC, GFP expression levels were similar in cells with control virus and those with INAM-expressing virus (Fig. 3 C). Transduction efficiency and expression from the lentivirus vector were adjusted using GFP expression (Fig. 3 C). Transduction efficiency and expression of triplicate samples from one experiment that is representative of three. (E) Augmented INAM expression in LN cells after polyC stimulation. WT mice were i.p. injected with 100 μg polyC or control buffer. After 24 h, inguinal, axillary, and mesenteric LN were harvested and RNA was extracted from the LN cells. The levels of the INAM mRNA were measured by real-time PCR. The results were confirmed in two additional experiments. Data represent mean ± SD.

**Figure 2. Sequence alignment of INAM and expression of INAM.** (A) Sequence alignment of human and mouse INAM. Asterisks, identical residues; double dots, conserved substitutions; single dots, semiconserved substitutions; box, N-glycosylation site; underline, transmembrane motif. (B) Immunoblot analysis of lysates of 293FT cells transfected with plasmid encoding Flag-tagged INAM. PNGase F, N-glycosidase. 2ME, 2-mercaptoethanol. (C and D) Quantitative RT-PCR for INAM expression in mouse tissue (C) and spleen cells (D). CD3+, CD19+, DX5+, CD11b+, CD11c+, mDC (CD11c+PDCA1−), and plasmacytoid DC (pDC, CD11c−PDCA1+) cells were isolated from splenocytes by cell sorting. Data are expressed as copy number per 10⁶ copies of HPRT. Data shown are means ± SD of triplicate samples from one experiment that is representative of three. (E) Augmented INAM expression in LN cells after polyC stimulation.
this NK activation was further enhanced by the addition of polyI:C (Fig. 3, D and E). Thus, polyI:C may also work for NK activation.

Direct cell–cell contact with NK cells was required for INAM in IRF-3−/− BMDC to function on enhancing NK activity (Fig. 3 F). We further confirmed this issue using WT BMDC by shRNA gene silencing. We silenced the INAM gene in BMDC using the lentiviral vector pLenti-dest-IRES-hrGFP and monitored expression by GFP. Because transfection efficiency was relatively high in this case compared with that shown in Fig. 3 C, the expression level of INAM had decreased by 75% in WT BMDC compared with the nonsilenced control (Fig. 3 G and Fig. S6 A). Although the level of the endogenous INAM protein was not very high, we confirmed that INAM protein was also decreased by shRNA with immunoblotting using anti-INAM pAb (Fig. S7 A). PolyI:C response of BMDC-inducible cytokines tested was not altered by INAM silencing in BMDC (Fig. S6 B). Yet this INAM RNA interference caused a significant decrease in NK cell IFN-γ production after co-culture of the INAM knockdown BMDCs and WT NK cells with polyI:C (Fig. 3 H). Collectively, these results indicate that INAM is downstream of IRF-3 in BMDC and is involved in the activation of NK cells by BMDC.

detected by ELISA (unpublished data). In addition, polyI:C-mediated NK activation occurred in BMDC expressing an INAM mutant lacking the cytoplasmic C-terminal region (193–327 aa; Fig. 4, A and B), excluding the participation of the cytoplasmic region in BMDC maturation signaling.

To investigate whether INAM could reconstitute NK-activating ability in IRF-3−/− BMDC, we transduced INAM into IRF-3−/− BMDC and incubated BMDC with NK cells. Overexpression of INAM in IRF-3−/− BMDC induced NK IFN-γ production and NK cytotoxicity against B16D8, and
Using an INAM–expressing stable BaF3 cell line (INAM/BaF3), we tested the possibility that INAM is an activating ligand for NK cells. As a positive control, we produced a stable BaF3 cell line expressing Rae-1α (Fig. 5 A) which is a ligand for the NK-activating receptor NKGe2D (Cerwenka et al., 2000). Although Rae-1α/BaF3 cells were easily damaged by IL-2–activated NK cells, INAM/BaF3 cells were not (Fig. 5 B). In this context, addition of IRF-3−/− BMDC to this culture with BaF3 and NK cells led to slight augmentation of IFN-γ induction irrespective of the presence of INAM on BaF3 cells (Fig. 5 C), and β2-microglobulin−/− BMDC barely affected the IFN-γ level (not depicted). These results suggest that an INAM-containing molecular matrix, rather than INAM alone, acts toward NK cells. Alternatively, INAM may selectively function with specific mDC molecules to activate NK cells.

INAM on NK cells is required for efficient NK activation

mDCs were previously shown to be required for efficient NK activation in vivo and in vitro (Akazawa et al., 2007a). We found that INAM was minimally present in BMDCs and NK cells and that polyI:C acts on both (Figs. S2 A; and Fig 3, D and E). Tetraspanin-like molecules tend to work as scaffolds for heteromolecular complexes that contain molecules functioning in a cis- or trans-adhesion manner to exert intercellular or extracellular functions. Thus, the function of INAM may not be confined to mDC, so we studied the function of INAM on NK cells. In NK cells, INAM was also inducible by polyI:C (Fig. 6 A and Fig. S2 A), and the induction of INAM was abrogated completely in IRF-3−/− NK cells and moderately in TICAM1−/− NK cells (Fig. 6 B). This suggests that polyI:C also acts on NK cells and induces INAM through IPS-1/IRF-3 activation when NK cells are co-cultured with BMDC and polyI:C.

To investigate whether INAM induced in NK cells is associated with BMDC-mediated NK activation, we performed the following experiments (Fig. 6 C). INAM–transduced IRF-3−/− BMDCs were incubated with polyI:C for 4 h, and then the aliquot was mixed with WT NK cells in the presence of polyI:C (Fig. 6 C, left two lanes). A moderate increase of IFN-γ was observed as in Fig. 3 D. In the remainder,
BMDC and NK cells are essential for BMDC-mediated NK activation. We next checked the function of the C-terminal stretch of INAM in NK activation. Although intact INAM works in NK cells to produce IFN-γ in response to BMDC (Fig. 6 F), introduction of C-del INAM into IRF-3−/− NK cells did not result in high induction of IFN-γ in response to BMDC (Fig. 4 C). Thus, INAM participates in NK activation through its cytoplasmic regions, which has no significant role in BMDC for NK activation.

Anti-tumor NK activation via INAM-expressing BMDCs in vivo

mDC-mediated NK activation induces anti-tumor NK cells, which cause regression of NK-sensitive tumors (Kalinski et al., 2005; Akazawa et al., 2007a). We tested the in vivo function of INAM-expressing BMDC using B16D8 tumor-bearing mice. BMDCs were used 24 h after transfection with either INAM/pLenti-IRES-hrGFP or control pLenti-IRES-hrGFP and injected twice a week s.c. around a preexisting tumor in tumor-implanted mice, beginning 11–13 d after tumor challenge. INAM-expressing BMDC significantly retarded tumor growth (Fig. 7 A). Tumor retardation was abrogated by depletion of NK1.1-positive cells (Fig. 7 B). Thus, INAM participates in NK activation through its cytoplasmic regions, which has no significant role in BMDC for NK activation.
cell–mediated innate anti-tumor immune responses in vivo (Kalinski et al., 2005; Akazawa et al., 2007a,b). Systemic administration of polyI:C unequivocally results in activation of peripheral NK cells (Lee et al., 1990; Sivori et al., 2004; Akazawa et al., 2007a). Although the molecular mechanism by which mDCs prime NK cells was still unclear, the TICAM–1 pathway and IPS–1 pathway have been reported to participate in polyI:C–mediated mDC maturation that drives NK activation (Akazawa et al., 2007a; McCartney et al., 2009; Miyake et al., 2009). We have shown in an earlier study that mDCs disrupted in the TLR3–TICAM–1 pathway abrogate NK cell activation (Akazawa et al., 2007a,b). In TICAM–1−/− mice, NK–sensitive implant tumors grew as well as those in WT mice depleted of NK cells (Akazawa et al., 2007a). mDCs gain high anti-tumor potential against B16D8 implant tumors through lentiviral transfer of TICAM–1, which is attributable to NK activation (Akazawa et al., 2007a). We further showed that TICAM–1 is a critical molecule for mDC to induce NK cell IFN–γ, as well as IPS–1, and participates in driving NK cytotoxicity to a lesser extent than IPS–1. In this paper, we clarified a molecular mechanism by which mDCs immediately promote NK cell functions in vitro and in vivo.

Our findings showed that IRF–3 is the transcription factor that is downstream of TICAM–1 responsible for maturing mDC to an NK-activating phenotype. We discovered that INAM, a membrane–associated protein, is up-regulated on the surface of polyI:C stimulation and activates NK cells via cell–cell contact. Furthermore, we found that NK cells also express INAM on their cell surface after polyI:C stimulation. mDC–NK activation by polyI:C can be reproduced with INAM–transduced mDC and NK cells, and adoptive transfer experiments show that INAM–overexpressing mDC may have therapeutic potential against MHC–low melanoma cells in an NK–dependent manner. These functional properties of INAM–expressing mDC fit the model of mDC priming NK activation. Ultimately, INAM appears to be the key molecule in the previously reported mechanism of mDC–NK contact activation.

After the submission of this manuscript, two papers were published that found that the MDA5–IPS–1 pathway in mDC is more important for driving NK activation, particularly in vivo (McCartney et al., 2009; Miyake et al., 2009). Our data also support this point using the IPS–1−/− mice we established (Fig. S1). However, polyI:C, when i.v. administered into mice, may stimulate other systemic cells in addition to CD8+ mDC in vivo (McCartney et al., 2009). The difference among the two (McCartney et al., 2009; Miyake et al., 2009) and this study may be attributed to the setting conditions, which are not always comparable. Moreover, it remains to be settled whether TICAM–1 and IPS–1 take the same INAM complex as a common NK activator in mature mDC and whether TLR3 (or MDA5) KO is equivalent to TICAM–1 (or IPS–1) KO in the mDC–NK activation model. In either case, however, up-regulation of mDC TICAM–1–mediated NK cytotoxicity and IFN–γ induction are feasible with polyI:C under three different conditions (Akazawa et al., 2007a; McCartney et al., 2009; Miyake et al., 2009). Our results infer that INAM participates in at least these mDC–NK interactions.

Fig. 7. INAM on BMDC retarded B16D8 tumor growth in an NK-dependent manner. (A) Tumor volume after DC therapy using BMDC expressing INAM. B16D8 cells were s.c. injected into C57BL/6 mice and, 11–13 d later, medium only (C) or BMDC (105/mouse) transfected with control lentivirus (○) or those with INAM–expressing lentivirus (■) were administered s.c. near the tumor at the time indicated by the open arrow. *, P = 0.043. Data represent mean ± SD. (B) Abrogation of INAM–dependent tumor regression by administration of NK1.1 Ab. For depletion of NK cells, antiNK1.1 mAb was injected i.p. 1 d before treatment of BMDC (arrowheads). Tumor volume in every mouse group was sequentially monitored. Data represent mean ± SD. (n = 3) and are representative of two experiments. Statistical analyses were made with the Student’s t test. **, P = 0.017.

NK cells (Fig. 8A). TRAIL and granzyme B were induced in NK cells by the addition of polyI:C to the mixture, and INAM expression in BMDC up-regulated mRNA levels of TRAIL and granzyme B (Fig. 8A). In vivo administration studies were performed with polyI:C–treated WT BMDC or INAM–expressing IRF–3−/− BMDC to test their ability to up-regulate the mRNA levels of TRAIL and granzyme B in NK cells in draining LN (Fig. 8B). INAM–expressing IRF–3−/− BMDC showed comparable abilities to up-regulate the killing effectors with polyI:C–treated BMDC (Fig. 8B). Collectively, INAM has therapeutic potential for NK–sensitive tumors by activating NK cells.

DISCUSSION

Previous studies demonstrated that mDC–NK interaction leads to direct NK activation and damages NK target cells in vitro (Gerosa et al., 2002; Sivori et al., 2004; Akazawa et al., 2007a; Lucas et al., 2007). In addition, mDCs initiate NK cell–mediated innate anti-tumor immune responses in vivo (Kalinski et al., 2005; Akazawa et al., 2007a,b). Systemic administration of polyI:C unequivocally results in activation of peripheral NK cells (Lee et al., 1990; Sivori et al., 2004; Akazawa et al., 2007a). Although the molecular mechanism by which mDCs prime NK cells was still unclear, the TICAM–1 pathway and IPS–1 pathway have been reported to participate in polyI:C–mediated mDC maturation that drives NK activation (Akazawa et al., 2007a; McCartney et al., 2009; Miyake et al., 2009). We have shown in an earlier study that mDCs disrupted in the TLR3–TICAM–1 pathway abrogate NK cell activation (Akazawa et al., 2007a,b). In TICAM–1−/− mice, NK–sensitive implant tumors grew as well as those in WT mice depleted of NK cells (Akazawa et al., 2007a). mDCs gain high anti-tumor potential against B16D8 implant tumors through lentiviral transfer of TICAM–1, which is attributable to NK activation (Akazawa et al., 2007a). We further showed that TICAM–1 is a critical molecule for mDC to induce NK cell IFN–γ, as well as IPS–1, and participates in driving NK cytotoxicity to a lesser extent than IPS–1. In this paper, we clarified a molecular mechanism by which mDCs immediately promote NK cell functions in vitro and in vivo.

Our findings showed that IRF–3 is the transcription factor that is downstream of TICAM–1 responsible for maturing mDC to an NK-activating phenotype. We discovered that INAM, a membrane–associated protein, is up-regulated on the surface of polyI:C stimulation and activates NK cells via cell–cell contact. Furthermore, we found that NK cells also express INAM on their cell surface after polyI:C stimulation. mDC–NK activation by polyI:C can be reproduced with INAM–transduced mDC and NK cells, and adoptive transfer experiments show that INAM–overexpressing mDC may have therapeutic potential against MHC–low melanoma cells in an NK–dependent manner. These functional properties of INAM–expressing mDC fit the model of mDC priming NK activation. Ultimately, INAM appears to be the key molecule in the previously reported mechanism of mDC–NK contact activation.

After the submission of this manuscript, two papers were published that found that the MDA5–IPS–1 pathway in mDC is more important for driving NK activation, particularly in vivo (McCartney et al., 2009; Miyake et al., 2009). Our data also support this point using the IPS–1−/− mice we established (Fig. S1). However, polyI:C, when i.v. administered into mice, may stimulate other systemic cells in addition to CD8+ mDC in vivo (McCartney et al., 2009). The difference among the two (McCartney et al., 2009; Miyake et al., 2009) and this study may be attributed to the setting conditions, which are not always comparable. Moreover, it remains to be settled whether TICAM–1 and IPS–1 take the same INAM complex as a common NK activator in mature mDC and whether TLR3 (or MDA5) KO is equivalent to TICAM–1 (or IPS–1) KO in the mDC–NK activation model. In either case, however, up-regulation of mDC TICAM–1–mediated NK cytotoxicity and IFN–γ induction are feasible with polyI:C under three different conditions (Akazawa et al., 2007a; McCartney et al., 2009; Miyake et al., 2009). Our results infer that INAM participates in at least these mDC–NK interactions.
PolyI:C activates IRF-3 through the two pathways involving the adaptors IPS-1 and TICAM-1 (Yoneyama et al., 2004; Kato et al., 2006; Matsumoto and Seya, 2008). The two pathways share the complex of IRF-3–activating kinase, NAP1, IKK-α, and TBK1 that is downstream of adaptors (Sasai et al., 2006). Nevertheless, these pathways are capable of inducing several genes unique to each adaptor. Although IFN-α production by in vivo administration of polyI:C is largely dependent on the IPS-1 pathway, IL-12p40 is mainly produced by the TICAM-1 pathway (Kato et al., 2006). Therefore, it is not surprising that INAM induction is predominant in the TICAM-1 pathway in polyI:C-stimulated BMDC (Fig. 3 A). What happens in INAM induction is predominant in the TICAM-1 pathway (Kato et al., 2006; Brilot et al., 2007; Lucas et al., 2007; Huntington et al., 2009). However, we did not observe decreased IL-15 expression in the TICAM-1−/− BMDC that could not activate NK cells (Fig. 1 E). Several molecules, such as B7-H6/NKp30 (Brandt et al., 2009), CD48/2B4 (Kubin et al., 1999), and NKG2D ligands/NKG2D (Cerwenka et al., 2000), have been identified as ligand/receptor molecules in mDC–NK reciprocal activation by in vitro coculture. In vivo coculture systems (Fig. S1), the IPS–1 pathway in BMDC has a pivotal role in not only type I IFN but also IL-15 induction. INAM identified in this paper serves a unique function in the in vivo induction of NK activation and may offer a tool to investigate the mDC–NK reciprocal activation by in vitro coculture.

In contrast, INAM–transduced IRF-3−/− NK cells produced IFN-γ in concert with BMDCs like WT NK cells (Fig. 6 F). So far we have no evidence suggesting that this kind of INAM overexpression is actually occurring in vivo. However, introduction of C-del INAM into IRF-3−/− NK cells did not result in high induction of IFN-γ in response to BMDC (Fig. 4 C). Together with the data on INAM expression in BMDC, this infers that the INAM cytoplasmic region signals for NK activation in NK cells.

In this study, IL-15 was found to be up-regulated by polyI:C in BMDC. The remaining NK activity in the resting population of NK cells co-cultured with TICAM-1−/− BMDC and polyI:C (Fig. 1 B) suggests that IL-15 has some effect in our system, and other studies suggest this as well (Ohteki et al., 2006; Brilot et al., 2007; Lucas et al., 2007; Huntington et al., 2009). However, we did not observe decreased IL-15 expression in the TICAM-1−/− BMDC that could not activate NK cells (Fig. 1 E). Several molecules, such as B7-H6/NKp30 (Brandt et al., 2009), CD48/2B4 (Kubin et al., 1999), and NKG2D ligands/NKG2D (Cerwenka et al., 2000), have been identified as ligand/receptor molecules in mDC–NK reciprocal activation by in vitro co-culture. In vitro co-culture systems (Fig. S1), the IPS–1 pathway in BMDC has a pivotal role in not only type I IFN but also IL-15 induction. INAM identified in this paper serves a unique function in the in vivo induction of NK activation and may offer a tool to investigate the mDC–NK reciprocal activation by in vitro co-culture.
INAM-expressing stable BaF3 cell lines (INAM/BaF3) did not reveal a function as an NK cell-activating ligand. NK cell cytotoxicity is directed against Rae-1α/BaF3 cells but not against INAM/BaF3 cells (Fig. 5). Therefore, INAM does not represent a typical NK cell-activating ligand. For NK activation, INAM on BMDC appears to require other molecules that are expressed in BMDC but not in BaF3.

INAM has four transmembrane regions, similar to the cell adhesion tetraspanins, which may support cell–cell contact (Levy and Shoham, 2005). Tetraspanins provide a scaffold that facilitates complex formation with associated proteins. INAM on BMDC and NK cells may use cell–cell interaction to assemble in a synaptic formation to activate NK cells. Because the protein components of the tetraspanin complexes are cell specific, we are interested in finding partners for INAM that might participate in efficient BMDC–NK interaction. TLR-inducible cell–cell contact may occur through INAM in an immune cell-specific manner. Gene disruption of this INAM will facilitate clarifying this issue. The identification of INAM defines a novel pathway in mDC–NK reciprocal interaction. This study will lead to further research on the molecules that form complexes on BMDC and NK cells to facilitate BMDC–NK interaction.

MATERIALS AND METHODS

Mice. All mice were backcrossed with C57BL/6 mice more than seven times before use. TICAM-1−/− (Akazawa et al., 2007a) and IP-10−/− mice were generated in our laboratory. IRF-3−/− mice (Sato et al., 2000) and IRF-7−/− mice (Honda et al., 2005) were provided by T. Taniguchi (University of Tokyo, Tokyo, Japan). All mice were maintained under specific pathogen-free conditions in the animal facility of the Hokkaido University Graduate School of Medicine. Animal experiments protocols and guidelines were approved by the Animal Safety Center, Hokkaido University, Japan.

Cells. The B16D8 cell line was established in our laboratory as a subline of B16 melanoma (Tanaka et al., 1998). This subline was characterized by its expression of Rae-1 and INAM on BaF3 cells but not in B16D8. For culture, B16D8 cells were maintained in RPMI 1640/10% FCS/2 µM 2ME/5 ng/ml IL-3. Mouse BMDCs were prepared as previously reported (Akazawa et al., 2007a). Mouse NK cell line BaF3 was obtained from American T ype Culture Collection and cultured in RPMI 1640/10% FCS/2 µM 2ME/5 ng/ml IL-3. Mouse NK cells (DX5+ cell) were positively isolated with MACS Beads (Miltenyi Biotec). Mouse BMDCs were prepared as previously reported (Akazawa et al., 2007a).

For purification of cells from spleen or LN, these tissues were treated with 400 IU MandleU/ml collagenase D (Roche) at 37°C for 25 min in HBSS (Sigma-Aldrich). Then EDTA was added, and the cell suspension was centrifuged for 10 min at 4°C, and the cell pellet was resuspended in 5 ml of 10 mg/ml NHS-sulfobiotin (Vector Laboratories) for 1 h at room temperature. Cells were washed in HBS three times and then solubilized with 10 ml of 10 mg/ml lytic buffer, spleenocytes and LN cells were stained with CD3ε-PE, CD19-PE, DX5-PE, CD11b-PE, and CD11c-PE (eBioscience) and sorted by a FACSAria II (BD). The purity of sorted cells was >98%.

Construction and expression. Mouse INAM cDNA (Accession number: AF007781) was obtained from RIKEN and cloned into expression vector pEFBOS and pLenti-IRES-hrGFP, both of which provide the specialized components needed for expression of a recombinant C-terminal FLAG fusion (Akazawa et al., 2007a). For construction of shRNA-expressing lentivirus vector, The Clal–Xhol fragment of pLent6-blockdist-dest (Invitrogen) was inserted into pLenti-IRES-hrGFP at the site of Clal and Xhol. This vector was named pLenti-dest-IRES-hrGFP (pLDIG). INAM sequence 5′-CTTCTCTCCGG-GTTAGTATCT-3′ was targeted for INAM knockdown (shINAM/ pLDIG) and 5′-AGTCTGACATCTTACTA-3′ was used for negative control (shControl/pLDIG). We used a gene-expression kit, Lentiviral system (Invitrogen), as previously described (Akazawa et al., 2007a). Four plasmids (one of the pLenti vectors, pL1, pL2, and pLP/VSVG) were transfected into 293 FT packaging cells, and the viral particles for transfection were prepared according to the manufacturer’s protocol. The 100× concentrated virus particles were produced after centrifugation of 8,000 × g at 4°C for 16 h. Lentivirus produced by pLenti-IRES-hrGFP and pLDBG could be titered by GFP expression using flow cytometry. Because the lentivirus vector pLenti-IRES-hrGFP has the IRES-GFP region, we prepared negative control virus by pLenti-IRES-hrGFP without construct. Infection efficiency for BMDC was high with the control vector compared with the INAM-expressing lentivector (Fig. S6 A).

Real-time PCR. BMDCs were harvested after 4 h of stimulation by 100 ng/ml LPS, 50 µg/ml polyI:C, 1 µg/ml Pm,CSK, (Pam3), 100 nM mycoplasma macrophage-activating lipopeptide-2 (Malp-2), 10 µg/ml Cpg, and 2,000 IU/ml IFN-α (Ebihara et al., 2007). Mouse tissues (heart, stomach, small intestine, lung, brain, muscle, liver, kidney, thymus, and spleen) were collected from C57BL/6. Spleenocytes were stained with CD3-PE, CD19-PE, DX5-PE, CD11b-PE, CD11c-FITC, and PDCA1-PE (eBioscience) and sorted by FACSaria (BD). Purity was >98% in each population. For RNA extraction, we used the RNeasy kit (Invitrogen). After removal of genomic DNA by treatment with DNase, randomly primed cDNA strands were generated with Moloney mouse leukemia virus reverse transcription (Promega). RNA expression was quantified by quantitative RT-PCR, with gene-specific primers (IL-15 forward, 5′-TAACTAGGCTGGCATTTGA-3′; IL-15 reverse, 5′-ACCTACACTGACACAGCCTA-3′; IFN-γ forward, 5′-CAACTGATGAGTACCCGCTA-3′; IFN-γ reverse, 5′-TGTTGATACAGGCCGACTTGTG-3′; and HPRT forward, 5′-TGTTGATACAGGCCGACTTGTG-3′ and reverse, 5′-GAGGTTAGGCTGCGCTATAGGCT-3′ and values were normalized to the expression of β-actin mRNA or HPRT mRNA.

Other primers for PCR were designed using Primer Express software (Applied Biosystems) for another experiment. The following primers were used for PCR: β-actin forward, 5′-CCCTGGCAACCAGCAACT-3′ and reverse, 5′-GCCGATCCACCCCGGACATCT-3′; granzyme B forward, 5′-TCTGCTACTCTGTCACACTTGC-3′ and reverse, 5′-ATGATCTCCCTCGCTGACCTTTG-3′; IFN-α forward, 5′-CTGCTGCTGTCCTGAGACATCT-3′ and reverse, 5′-AGGCCACAGGGCTGTGTTTCT-3′; TRAIL (Tnfsf10) forward, 5′-CTTCAACAACAGGATAAGCAGC-3′ and reverse, 5′-TCTGCTTGGAGAAGAAGCTA-3′ and 1,000 bp (II12b), forward, 5′-AAATGTCTGGTGCAAGCTA-3′ and reverse, 5′-ATGCCACATTGCTCTGCAATG-3′.

Anti-INAM pAb. C-terminal INAM (cINAM; 191–314 aa) was subcloned between the Ndel and Sal1 sites of pColdI vector (Takara Bio Inc.). 6× His-C-terminal INAM (cINAM; 191–314 aa) was subcloned between the Ndel and Sal1 sites of pColdI vector (Takara Bio Inc.). 6× His-tagged cINAM protein was expressed in BL21 by manufacturer’s methods. The cells were sonicated in 20 mM Tris-HCl, 150 mM NaCl, 1 mM PMSF and 7 µl Uvea, pH 7.4, on ice. Expression products of cINAM were purified using the HisTrap HP kit (GE Healthcare). The extracted proteins were refolded by stepwise dialysis against decreasing amounts of urea. Rabbit anti-cINAM polyclonal Ab was produced with the cINAM proteins by standard protocol. IgG was purified by precipitation with 33% ammonium sulfate, dialyzed against PBS.

Surface labeling with biotin. Biotinylation of cell surface proteins was performed according to the reported method (Tsuji et al., 2001). Biotinylated cINAM protein was expressed in BL21 by manufacturer’s methods. The cells were sonicated in 20 mM Tris-HCl, 150 mM NaCl, 1 mM PMSF and 7 µl Uvea, pH 7.4, on ice. Expression products of cINAM were purified using the HisTrap HP kit (GE Healthcare). The extracted proteins were refolded by stepwise dialysis against decreasing amounts of urea. Rabbit anti-cINAM polyclonal Ab was produced with the cINAM proteins by standard protocol. IgG was purified by precipitation with 33% ammonium sulfate, dialyzed against PBS.

Immunoblot analysis. Lysates were harvested 24 h after transfection of Flag-tagged INAM/pEFBOS into 293FT cells and treated with N-glycosidase F.
Confluent monolayer BMDCs were co-cultured with freshly isolated NK cells (BMDC/NK = 1:2–1:5) with or without 10 µg/ml polyIC for 24 h (Akazawa et al., 2007a). In some experiments, function of BMDCs and NK cells was modified by lentivirus vector before BMDC/NK co-culture. BMDC–NK interaction.

BMDC–NK interaction. BMDCs and NK cells were infected with control or INAM-expressing lentivirus as described previously (Akazawa et al., 2007a). In some experiments, function of BMDCs and NK cells was modified by lentivirus vector before BMDC/NK co-culture. IRF-3 (indicated as day 0). For DC therapy, BMDCs were prepared by transfecting with BL21 bacterial lysate (where the INAM immunogen was produced) that contained no INAM peptide.

Online supplemental material. TICAM-1–inducible genes encoding putative membrane proteins relevant for this study are summarized in Table S1. Fig. S1 shows KO mice results suggesting that both IPS-1 and TICAM-1 in BMDC participate in polyIC-driven NK activation. Data presented in Fig. S2 characterizes the in vivo polyIC response of INAM in LN cells. Figs. S3 and S4 demonstrate the properties of surface-expressed INAM analyzed by immunoprecipitation/blotting and confocal microscopy, respectively. Fig. S5 mentions the cytokine expression and maturation profiles of INAM-overexpressing BMDC. Fig. S6 shows the effect of gene silencing of INAM on the polyIC–mediated cytokine-inducing profile in BMDC. Two pieces of data presented in Fig. S7 confirm the presence of the INAM protein in polyIC BMDCs and NK cells. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20091573/DC1.

We thank Drs. T. Akazawa and N. Inoue (Osaka Medical Center for Cancer, Osaka, Japan) for their valuable discussions. Thanks are also due to many discussions by our laboratory members. Particularly, extensive English review by Dr. Hussein H. Aly is gratefully acknowledged.

This project was supported by Grants-in-Aid from the Ministry of Education, Science, and Culture and the Ministry of Health, Labor, and Welfare of Japan, Mitsubishi Foundation, Mochida Foundation, NorthTec Foundation Waxman Foundation, and Yakult Foundation.

The authors declare no financial or commercial conflict of interest.

Submitted: 20 July 2009
Accepted: 13 October 2010

REFERENCES


Published November 8, 2010

JEM VOL 207, November 22, 2010

2685


```
Published November 8, 2010

INAM regulates NK activation | Ebihara et al.
```

Downloaded from jem.rupress.org on January 24, 2011


